EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--ProUroCare Medical Inc. (OTCBB: PUMD), announced today that the physician at one of three major participating centers has completed his portion (ten patients) of the study of the ProUroScanTM prostate imaging system. The study is intended to identify images of the prostate. The results from these clinical trials will be used to support ProUroCare’s future application to the Food and Drug Administration for 510(k) clearance of the ProUroScan system.
